BRAK/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse
Authors:
Open Access
- 1 January 2009
- journal article
- research article
- Published by Biomedical Research Press in Biomedical Research
- Vol. 30 (5) , 315-318
Abstract
SCID mice are a model of human severe combined immunodeficiency disease and are deficient in B cell function in addition to T cell function. Tumors from other species are easily transplanted into SCID mice and will grow without being rejected. We previously reported that the chemokine BRAK/CXCL14 is expressed in normal cells but its expression is down regulated in an in vitro cancer progression model, suggesting that it has the potential for antitumor activity. Here we report that the growth of BRAK/CXCL14 expression vector-transfected oral cancer cells was completely (100%) suppressed in SCID mouse xenografts even though mock-vector introduced control tumor cells grew well with 100% of animals developing tumors. In addition, suppression of xenografts was much faster and the rate was much higher in SCID mice than in T cell functiondeficient nude mice. These data indicate the possibility that BRAK expression inhibits tumor cell establishment by regulating interactions between tumor stem cells and NK cells and/or suppressing formation of tumor microvessels.Keywords
This publication has 25 references indexed in Scilit:
- Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinomaCancer Science, 2009
- The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cellsOncogene, 2008
- Metastasis: a therapeutic target for cancerNature Clinical Practice Oncology, 2008
- A balance between NF-Y and p53 governs the pro- and anti-apoptotic transcriptional responseNucleic Acids Research, 2008
- BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cellsBiochemical and Biophysical Research Communications, 2006
- TGF-β antagonists: Why suppress a tumor suppressor?Journal of Clinical Investigation, 2002
- The Hallmarks of CancerCell, 2000
- Cloning of BRAK, a Novel Divergent CXC Chemokine Preferentially Expressed in Normal versus Malignant CellsBiochemical and Biophysical Research Communications, 1999
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989
- Genetic Alterations during Colorectal-Tumor DevelopmentNew England Journal of Medicine, 1988